Evidence map›Paper›PMID 37202100›Full record

ReviewZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2022

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.

Wei Yuan, Shizhong Zhang, Honghu Zhu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wei Yuan1. Medical College of China Three Gorges University, Yichang 443000, Hubei Province, China.
Shizhong Zhang1. Medical College of China Three Gorges University, Yichang 443000, Hubei Province, China.
Honghu Zhu3. Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
China Three Gorges University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy. AML patients with

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3HumansMutationPrognosisProtein Kinase InhibitorsRecurrenceTumor MicroenvironmentAntineoplastic AgentsFLT3 protein, humanfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsAcute myeloid leukemiaInhibitorResistanceReviewTargeted therapyTyrosine kinase

Identifiers

PMID37202100
PMCPMC10264991
OpenAlexW4295887080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.